Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata

    Jung Eun Kim, Yu-Jin Lee, Kyung-Jae Lee, Song-Hee Park, Hoon Kang
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study involved 10 severe Alopecia Areata (AA) patients and investigated the effects of allogenic human mesenchymal stem cells (hMSCs) from healthy donors on the patients' peripheral blood mononuclear cells (PBMCs). The results showed that co-culturing with hMSCs suppressed the activation levels of CD4+INF-γ+ T cells and induced the differentiation of CD4+Foxp3+ regulatory T cells in AA patients. The hMSC treatment also significantly inhibited the mRNA levels of proinflammatory cytokines and chemokines. These findings suggest that allogenic hMSC treatments could potentially induce immune tolerance and anti-inflammatory effects in severe AA patients, offering a potential therapeutic approach.
    Discuss this study in the Community →

    Research cited in this study

    19 / 19 results